Detalhe da pesquisa
1.
Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.
Mol Ther
; 22(11): 1992-2003, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24930599
2.
Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia.
PLoS Negl Trop Dis
; 13(2): e0007132, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30789910
3.
A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia.
PLoS Negl Trop Dis
; 13(1): e0006988, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30653490
4.
Safety and Effectiveness of Sodium Stibogluconate and Paromomycin Combination for the Treatment of Visceral Leishmaniasis in Eastern Africa: Results from a Pharmacovigilance Programme.
Clin Drug Investig
; 37(3): 259-272, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-28066878
5.
Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.
PLoS One
; 8(3): e57726, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23526949